AcelRx Pharmaceuticals, Inc.: U.S. launch of DSUVIA (sufentanil sublingual tablet 30 mcg) exp. 1Q19. Recently approved for mgmt of acute pain severe enough to require opioid analgesic (adult patients in certified medically supervised healthcare settings). Also developing Zalviso (Ph 3) in the US as an innovative patient-controlled analgesia system for moderate-to-severe acute pain in medically supervised settings.
Website:
Address:
351 Galveston Drive
Redwood City, CA 94063
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.